Sign In
glob
Find HeartFlow

Category: Newsroom

SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography

SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography   MOUNTAIN VIEW, Calif. – July 16, 2024 – HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on the use of coronary computed tomography angiography (coronary CTA) […]

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease Technology offers benefits of HeartFlow Plaque Analysis with the new addition of 3D interactive capabilities, integrated with lesion specific FFRCT values   WASHINGTON, D.C. — July 18, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) […]

HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage

HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage Coverage policy determination initiated with 5 Medicare MACs for HeartFlow’s AI-QCT revolutionizing cardiovascular care for patients   MOUNTAIN VIEW, Calif. – June 3, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for […]

HeartFlow’s Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study

HeartFlow’s Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study MOUNTAIN VIEW, Calif. – May 15, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its REVEALPLAQUE study, highlighting the accuracy of its Plaque Analysis, was published in […]

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients First published evidence: FFRCT-guided diagnosis and treatment drastically reduces mortality in peripheral artery disease (PAD) patients MOUNTAIN VIEW, Calif. – May 8, 2024 — In a groundbreaking development, a study published in the Journal of Vascular Surgery reveals […]

HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease

HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease The largest prospective registry of its kind will build upon clinical data supporting the use of plaque insights to empower clinical decision making for patients with suspected coronary artery disease MOUNTAIN VIEW, Calif. – March 26, […]

HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography

HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography  HeartFlow’s non-invasive AI driven FFRCT predicts patient outcomes as effectively as the gold-standard invasive FFR out to 10 years MOUNTAIN VIEW, Calif. – March 12, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart […]

HeartFlow Announces New Reimbursement Code and Increased Payment for FFRCT

HeartFlow Announces New Reimbursement Code and Increased Payment for FFRCT Category I CPT code for Fractional Flow Reserve derived from Computed Tomography will provide broader access to HeartFlow’s AI-powered technology, a standard of care for evaluating and treating coronary artery disease MOUNTAIN VIEW, Calif. – January 23, 2024 — HeartFlow, Inc., a leader in non-invasive […]

HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease with FFRCT Analysis

HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis This patient milestone and the recent launch of Plaque Analysis and RoadMapTM Analysis further solidify HeartFlow as a pioneer in AI-enabled CAD diagnostics MOUNTAIN VIEW, Calif. – January 3, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) […]

TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights

TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights New Clinical Data Support Use of Lesion-Specific FFRCT  for Diagnosis and Treatment of Patients With Coronary Artery Disease MOUNTAIN VIEW, Calif. – October 25, 2023 — HeartFlow, Inc., a leader in non-invasive integrated artificial intelligence (AI) heart care solutions, today announced results from […]

cert logo hitrust.7394f2b.cda83af2e008d8cc68f55103dbde7712

The information provided by the HeartFlow Analysis is intended to be used in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement. The HeartFlow Analysis may not be appropriate for all patients. See indications for use for more information. The HeartFlow Analysis, featuring the FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States of America. The FFRCT Analysis and HeartFlow Planner are CE Marked in Europe and the United Kingdom and approved in Japan and Canada. The HeartFlow Analysis, featuring FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, is commercially available in the United States. The FFRCT Analysis and HeartFlow Planner are commercially available in the United Kingdom. The FFRCT Analysis is also commercially available in Europe, Japan, and Canada.

© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041

206324211 v1

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます！

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.